Biostax (BTAX) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		82,762,035

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 185,447	$ 493,885
Deposits	5,500
Investment in common stock		2,645,000
Total current assets	190,947	3,138,885
Total assets	190,947	3,138,885
Current Liabilities:
Accounts payable	1,385,007	2,184,848
Notes payable	671,481	3,070,208
Accrued payroll	336,002	3,421,176
Accrued liabilities	176,057	239,558
Accrued interest	134,678	564,300
Due to related parties	90,000	891,420
Undocumented investor advances		715,631
Total current liabilities	2,793,225	11,087,141
Total liabilities	2,793,225	11,087,141
Commitments and Contingencies (Note 8)
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 shares authorized; 82,198,697 and 483,714 shares issued and outstanding respectively	8,220	49
Additional paid in capital	380,068,768	371,473,810
Stock issuances due	10,303	10,303
Accumulated deficit	(382,689,569)	(379,432,418)
Total stockholders’ deficit	(2,602,278)	(7,948,256)
Total liabilities and stockholders’ deficit	$ 190,947	$ 3,138,885

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	82,198,697	483,714
Common stock, shares outstanding	82,198,697	483,714

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Selling, general and administrative	$ 420,862	$ 114,567	$ 894,596	$ 438,583
Research and development				152,667
Total operating expense	420,862	114,567	894,596	591,250
Loss from operations	(420,862)	(114,567)	(894,596)	(591,250)
Other income (expense):
Gain on issuance of Forte license			3,165,151
(Loss) gain on settlement of obligations and conversion of debt	(1,467,271)	603,204	(1,169,691)	711,896
Impairment loss on common shares		(3,105,000)	(2,645,000)	(3,105,000)
Charge from warrant modification and debt settlement	(594,288)		(1,605,913)
Receipt of common shares		5,761,500		5,761,500
Interest expense	(11,034)	(32,197)	(107,102)	(164,731)
Gain on derivative liability valuation				1,178,230
Total other income	(2,072,593)	3,227,507	(2,362,555)	4,381,895
Net (loss) income	$ (2,493,455)	$ 3,112,940	$ (3,257,151)	$ 3,790,645
Basic (loss) income per share	$ (0.04)	$ 6.44	$ (0.16)	$ 7.86
Diluted (loss) earnings per share	$ (0.04)	$ 0.24	$ (0.16)	$ 0.29
Basic weighted average shares outstanding	60,089,305	483,714	20,643,181	482,527
Diluted weighted average shares outstanding	60,089,305	12,990,932	20,643,181	12,989,745

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020	$ 48	$ 371,341,120	$ 10,303	$ (383,018,452)	$ (11,666,981)
Balance, shares at Dec. 31, 2020	476,504
Issuance of common stock upon conversion of notes and obligations	$ 1	56,479			56,480
Issuance of common stock upon conversion of notes and obligations, shares	5,402
Extinguishment of derivative liability upon conversion of debt		76,211			76,211
Effect of fractional shares upon reverse stock split
Effect of fractional shares upon reverse stock split, shares	1,808
Net Income (loss)				3,790,645	3,790,645
Balance at Sep. 30, 2021	$ 49	371,473,810	10,303	(379,227,807)	(7,743,645)
Balance, shares at Sep. 30, 2021	483,714
Balance at Dec. 31, 2021	$ 49	371,473,810	10,303	(379,432,418)	(7,948,256)
Balance, shares at Dec. 31, 2021	483,714
Issuance of common stock upon conversion of notes and obligations	$ 6,403	6,196,516			6,202,919
Issuance of common stock upon conversion of notes and obligations, shares	64,028,803
Net Income (loss)				(3,257,151)	(3,257,151)
Issuance of common stock upon exercise of warrants	$ 1,758	696,566			$ 698,324
Issuance of common stock upon exercise of warrant , shares	17,586,680				81,615,483
Charge resulting from warrant modification		1,605,913			$ 1,605,913
Issuance of common stock for services	$ 10	95,963			95,973
Issuance of common stock for services, shares	99,500
Balance at Sep. 30, 2022	$ 8,220	$ 380,068,768	$ 10,303	$ (382,035,431)	$ (2,602,278)
Balance, shares at Sep. 30, 2022	82,198,697

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (2,493,455)	$ 3,112,940	$ (3,257,151)	$ 3,790,645
Adjustments to reconcile net income to net cash flows (used in) operating activities:
Gain on issuance of license agreement			(3,165,151)
Loss (gain) on settlement of obligations			1,169,691	(711,896)
Loss on impairment on investment in common stock		3,105,000	2,645,000	3,105,000
Gain recognized upon receipt of common stock				(5,761,500)
Loss resulting from warrant modification	594,288		1,605,913
Change in value of derivative				(1,178,230)
Amortization of debt discount				34,789
Changes in operating assets and liabilities:
Deposits			(5,500)	200
Accounts payable			(75,895)	102,177
Accrued payroll			4,620	(20,244)
Net due to related parties				270,001
Accrued interest			116,929	129,943
Accrued liabilities			(35,321)	18,499
Net cash (used in) operating activities			(996,865)	(220,616)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from undocumented investor advances			6,369	240,000
Proceeds from notes payable			265,000
Proceeds from related parties			417,058
Net cash provided by financing activities			688,427	240,000
Net increase in cash and cash equivalents			(308,438)	19,384
Cash and cash equivalents at beginning of period			493,885	9,971
Cash and cash equivalents at end of period	$ 185,447	$ 29,355	185,447	29,355
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Conversion of debt and accrued interest to common stock			6,901,242	56,480
Stock issued for services			95,973
Reclassification to notes payable from accrued interest				$ 243,568

Company Overview

Company Overview	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview	1. Company Overview Immune Therapeutics Inc. (the “Company” or “IMUN”) is a Florida corporation trading on the OTC-Pink. The Company is a drug development and commercialization company. We identify, evaluate, and seek to acquire technologies in the medical device and drug development sectors with the intent to further develop them and move them to commercialization. Going Concern As of September 30, 2022, the Company had $ 185,447 2,602,278 3,257,151 For the nine months ended September 30, 2021, the Company reported net income of $ 3,790,645 Since our own financial resources are insufficient to satisfy our capital requirements, we may seek to sell additional equity or debt securities or obtain additional credit facilities. During the nine months ended September 30, 2022, we issued a total of 81,615,483 Historically, the Company has relied on the funding of operations through private equity financings and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Working capital on September 30, 2022 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Management is continuing to develop strategies to re-capitalize the Company and position it for future growth. Key steps to this process include: ● Improve the condition of the balance sheet via license arrangements and capital infusions. ● Identify and acquire late-stage assets for commercialization. ● Build out operational infrastructure to generate revenue opportunities to grow shareholder value. There can be no guarantees that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development. If the Company is unable to secure new working capital, other alternative strategies will be required. Historically, the Company has been able to acquire and develop assets, spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company has acted as an incubator for late-stage drug development. Management believes that this strategy can continue to be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present no definitive actions have been taken. There can be no guarantees that the Company will be successful in: ● Executing its restructuring plan; ● Securing adequate capital to continue operations; or ● Identifying and acquiring assets for future development. Company History Immune Therapeutics, Inc. (the “Company” or “IMUN”) was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014, changing our name to Immune Therapeutics, Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2021 (including the notes thereto) set forth in the Company’s Annual Report on Form 10- K for that period. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000 Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma, Inc. (“STAB”) reflects an asset impairment charge taken in the second quarter of 2022 and is carried at zero in the consolidated balance sheet. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. The Company did not incur any research and development costs during the nine months ended September 30, 2022. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of September 30, 2022 and 2021, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2022, and 2021, the Company does not have any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation On September 20, 2022, the Company issued 50,000 93,500 1.87 49,500 0.05 2,463 The Company did not issue any stock-based compensation awards during the nine months ended September 30, 2021. Net Income per Share For the nine-and three- month periods ended September 30, 2022, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. For the nine and three- month periods ended September 30, 2021, diluted income per share was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share for the periods ended in 202 are as follows: Schedule of Basic and Diluted Earnings per Share Three Months ended Nine Months ended September 30, 2021 Basic EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares (Denominator) 483,714 482,527 Basic EPS $ 6.44 $ 7.86 Diluted EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares 483,714 482,527 Weighted average common shares assuming exercise of outstanding warrants 12,507,218 12,507,218 Denominator 12,990,932 12,989,745 Diluted EPS $ 0.24 $ 0.29 Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022. In August 2020, the FASB issued ASU-2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contract in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon the adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. ASU 2020-06 will reduce the issue discount and result in less non-cash interest in the financial statements. ASU 2020-06 revises the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. The type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. ASU 2020-06 simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 23, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company has adopted ASU 2020-06 effective January 1, 2022. Management does not believe there are other significant accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Investment in Common Stock of S

Investment in Common Stock of Statera BioPharma, Inc.	9 Months Ended
	Sep. 30, 2022
Investment In Common Stock Of Statera Biopharma Inc.
Investment in Common Stock of Statera BioPharma, Inc.	Note 3. Investment in Common Stock of Statera BioPharma, Inc. In 2021, Cytocom, Inc., a former subsidiary of the Company (“Cytocom”), announced the completion of its merger with Cleveland BioLabs, Inc. (“CBLI”) which resulted in the Company’s receipt of 1,150,000 The Company evaluated the carrying value of the STAB common shares during the second quarter of 2022 and determined that an impairment loss of $ 362,250 362,250

Notes payable

Notes payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes payable	4. Notes payable During the nine-month period ended September 30, 2022 the Company reported the following activity in notes and accrued interest: ● The Company assigned $ 1,775,275 in notes to Forte Animal Health, Inc. (“Forte”) upon the receipt of release and assignments signed by these note holders in connection with the issuance of an Amended License Agreement. In connection with the Amended License Agreement, Forte issued 2,235,000 of its outstanding stock to the Company, representing 15% of the issued and outstanding shares of Forte. (Note 7). ● Certain note holders utilized $ 376,250 0.05 ● Certain note holders converted $ 1,209,206 0.05 ● The Company issued $ 265,000 0.05 Notes outstanding as of September 30, 2022 and December 31, 2021 are as follows: Schedule of Notes Payable September 30, 2022 December 31, 2021 Promissory notes issued in 2014 and 2015 and matured in 2015. Lenders earned interest at 10% and had a penalty rate of 5%. These notes were in default at December 31, 2021 and were settled in 2022 in connection with the Company’s recapitalization in 2022. - $ 70,000 Promissory notes issued in 2014 and 2015 and matured in 2015. Lenders earned interest at 10% 5% - $ 70,000 Promissory notes issued in 2016 and matured in 2017. Lenders earned interest at 2% 5% - 606,500 Promissory note issued in 2016 and matured in 2016. Lenders earned interest at 2% 5% - 37,000 Promissory notes issued in 2017 and matured in 2018. Lenders earn interest at 2% 5% 552,300 25,000 0.05 $ 25,000 577,300 Promissory note issued in 2018 and matured in 2019. Lender earned interest at 25% - 80,000 Promissory note issued in 2018 and matured in 2018. Lender earned interest at 2% 5% - 112,500 Promissory notes issued in 2018 and matured in 2019. Lenders earned interest at 2% 5% - 497,830 Promissory note issued in 2019 and matured in 2020. Lender earns 6% 231,481 231,478 Promissory note issued in 2019 and matured in 2019. Lender earned 6% - 10,000 Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15% 150,000 150,000 Promissory note issued in 2021 resulted from a Note Purchase Agreement with the original noteholder. The new notes reflected all principal, interest and penalties associated with the original instrument. The notes had an interest rate of 5% 7% 348,800 - 697,600 Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6% 0.05 65,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6% 0.05 200,000 - $ 671,481 $ 3,070,208 At September 30, 2022, the Company had $ 375,000

Capital Structure _ Common Stoc

Capital Structure – Common Stock and Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Capital Structure – Common Stock and Stock Purchase Warrants	5 Capital Structure – Common Stock and Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. Stock Warrants Warrant holders exercised 17,225,000 2,283,850 The following is a summary of outstanding common stock warrants as of September 30, 2022. Schedule of Outstanding Common Stock Warrants Expiration Date Number of Exercise Price Remaining Fourth Quarter 2022 9,811 $ 80 290 0.25 First Quarter 2023 4,000 $ 30 40 0.50 Second Quarter 2023 1,000 $ 200 0.75 Third Quarter 2023 501,500 $ 0.05 100 1.00 Third Quarter 2028 3,000 $ 70 6.00 Second Quarter 2032 28,995 $ 10 70 9.75 548,306 $ 0.05 290 Following is a summary of stock warrant activity for the nine months ended September 30 2022: Schedule of Stock Warrants Activity Number of Shares Exercise Weighted Average Price Warrants as of December 31, 2021 20,057,156 $ 2 290 $ 5.21 Issued - $ - $ - Expired and forfeited (2,283,850 ) $ 0.05 200 $ 126.76 Exercised (17,225,000 ) $ 0.05 $ 0.05 Warrants as of September 30, 2022 548,306 $ .05 70 $ 8.39 On June 29, 2022, the Company’s board of directors approved a resolution to clarify the anti-dilution protection granted to certain note and warrant holders. In connection with this board action, the Company recognized a non-cash charge of $ 1,605,913 Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Expected term (years) 0.63 Risk free rate 2.04 % Volatility 436 % Dividend yield - The average risk-free interest rate is based on the U.S. Treasury security rate in effect on June 29, 2022. We determined expected volatility using the historical closing stock price. The expected life was determined using the simplified method as we do not believe we have sufficient historical warrant exercise experiences on which to base the expected term.

Income Taxes _ Results of Opera

Income Taxes – Results of Operations	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes – Results of Operations	6. Income Taxes – Results of Operations There was no income tax expense reflected in the results of operations for the periods ended September 30, 2022 and 2021 because the Company has significant net loss operating carryforwards available to offset the potential tax liabilities. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year. For U.S. federal purposes the corporate statutory income tax rate was 21% ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.

License Agreement with Forte An

License Agreement with Forte Animal Health, Inc.	9 Months Ended
	Sep. 30, 2022
License Agreement With Forte Animal Health Inc.
License Agreement with Forte Animal Health, Inc.	7. License Agreement with Forte Animal Health, Inc. On July 8, 2021 the Company entered into an amended license agreement with Forte Animal Health, Inc (“Forte”). The initial license fee included the assignment of certain Company defaulted notes and other vendor and employee obligations. During the second quarter of 2022, these debtors associated with the assigned obligations completed the assignment of $ 1,775,275 264,790 1,125,086 In connection with the amended license agreement, Forte issued 2,235,000 15%

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events Settlement Agreement and Release On October 23, 2022 the Company entered into a Settlement Agreement and Release with a former board member that was a note holder as of September 30, 2022. The agreement provided for the utilization of $ 25,000 500,000 0.05 63,338 1.00 563,338 Amendment to Promissory Note and Settlement of Litigation On November 4, 2022, the Company and Ira Gaines agreed to a first amendment to a promissory note dated October 1, 2019 that included the following provisions: ● The maturity date of the amended note will be extended to September 1, 2023. ● The Company will make a $ 60,000 ● The $ 16,911 0.50 33,822 ● The $ 150,000 15% ● Interest accrued will be paid in common stock measured at the lower of $ 0.50 Upon the Company’s issuance of the 33,822 License signed with TaiwanJ Pharmaceuticals Co. Ltd. On September 30, 2022, the Company entered into an Intellectual Property License Agreement (the “ Agreement TaiwanJ Products This obligation, and costs associated with this agreement, will be reflected in the Company’s financial statements upon the license transfer which requires the Company to provide the non-refundable cash payment of $ 500,000 The Company also received a non-exclusive worldwide right to make, manufacture, and receive technical manufacturing assistance from TaiwanJ for the creation of the Products. The only territories excluded from the scope of the Agreement are any countries or territories in Asia, and any countries or territories barred or sanctioned by the United States government. We did not have any relationship with TaiwanJ prior to entering into the Agreement. The term of this Agreement is to be perpetual, but termination of the Agreement may occur upon (i) the Company providing sixty (60) days prior written notice to TaiwanJ of termination, (ii) termination of the agreement for a material breach of the agreement, and failure to cure that breach within ninety (90) days after receiving notice of such breach, (iii) the dissolution of the Company, or (iv) upon bankruptcy of either party, upon receiving sixty (60) days’ notice by Registered Mail. The Company may grant sublicenses under the Agreement. Upon the granting of any such sublicense, the Company will pay TaiwanJ royalties based on the stage of development of the Products. The Company will pay a royalty of 30% 10% 5% NDA Pursuant to the terms of the license in the Agreement, the Company shall adhere to a plan of development and attain certain milestones. As part of the Development Plan, the Company shall (i) use commercially reasonable efforts and cause its sublicenses to use commercially reasonable efforts to develop licensed Products, (ii) begin commercial sales of the Products in a country no less than eight (8) months after the first registration of the Products in that same country, and (iii) following commercialization, the Company must keep the Products reasonably available to the public. In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“ NAFDAC FDA The Company will be required to pay one-time payments and issuances of equity for the achievement of each of four milestones in the commercialization and development of the Products. In addition to the milestone payments, if there is any year that the Company is not required to pay a Milestone Payment, the Company will pay a royalty percentage payment based on the total net sales due within sixty (60) days after the end of each calendar quarter (the “ Royalty Payment If the Company fails to make any of the above-described payments upon their designated due date, the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due. TaiwanJ will maintain, protect, and defend all patent-related intellectual property and the Company will reimburse TaiwanJ for any expenses related to intellectual property patent payments that exclusively benefit the Company. If either the Company or TaiwanJ becomes aware of any possible or actual infringement of any patent rights, then each party will notify the other, and provide it with details of such an infringement. Both the Company and TaiwanJ are limited in liability to the total amounts paid under this Agreement for any damages arising from negligence, strict liability, or any other equitable theory. Further, both the Company and TaiwanJ agree to indemnify and hold harmless each other, and their respective agents, for any claims or costs arising from this Agreement or any sublicenses for any cause of action relating to any product, process, service made, used, or sold pursuant to this Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2021 (including the notes thereto) set forth in the Company’s Annual Report on Form 10- K for that period.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma, Inc. (“STAB”) reflects an asset impairment charge taken in the second quarter of 2022 and is carried at zero in the consolidated balance sheet. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. The Company did not incur any research and development costs during the nine months ended September 30, 2022.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of September 30, 2022 and 2021, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2022, and 2021, the Company does not have any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation On September 20, 2022, the Company issued 50,000 93,500 1.87 49,500 0.05 2,463 The Company did not issue any stock-based compensation awards during the nine months ended September 30, 2021.
Net Income per Share	Net Income per Share For the nine-and three- month periods ended September 30, 2022, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. For the nine and three- month periods ended September 30, 2021, diluted income per share was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share for the periods ended in 202 are as follows: Schedule of Basic and Diluted Earnings per Share Three Months ended Nine Months ended September 30, 2021 Basic EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares (Denominator) 483,714 482,527 Basic EPS $ 6.44 $ 7.86 Diluted EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares 483,714 482,527 Weighted average common shares assuming exercise of outstanding warrants 12,507,218 12,507,218 Denominator 12,990,932 12,989,745 Diluted EPS $ 0.24 $ 0.29
Recent Accounting Standards	Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022. In August 2020, the FASB issued ASU-2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contract in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon the adoption of ASU 2020-06, convertible debt proceeds, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. ASU 2020-06 will reduce the issue discount and result in less non-cash interest in the financial statements. ASU 2020-06 revises the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. The type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. ASU 2020-06 simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 23, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company has adopted ASU 2020-06 effective January 1, 2022. Management does not believe there are other significant accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Basic and Diluted Earnings per Share	Schedule of Basic and Diluted Earnings per Share Three Months ended Nine Months ended September 30, 2021 Basic EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares (Denominator) 483,714 482,527 Basic EPS $ 6.44 $ 7.86 Diluted EPS Income available to common shareholders (Numerator) $ 3,112,940 $ 3,790,645 Weighted average common shares 483,714 482,527 Weighted average common shares assuming exercise of outstanding warrants 12,507,218 12,507,218 Denominator 12,990,932 12,989,745 Diluted EPS $ 0.24 $ 0.29

Notes payable (Tables)

Notes payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes outstanding as of September 30, 2022 and December 31, 2021 are as follows: Schedule of Notes Payable September 30, 2022 December 31, 2021 Promissory notes issued in 2014 and 2015 and matured in 2015. Lenders earned interest at 10% and had a penalty rate of 5%. These notes were in default at December 31, 2021 and were settled in 2022 in connection with the Company’s recapitalization in 2022. - $ 70,000 Promissory notes issued in 2014 and 2015 and matured in 2015. Lenders earned interest at 10% 5% - $ 70,000 Promissory notes issued in 2016 and matured in 2017. Lenders earned interest at 2% 5% - 606,500 Promissory note issued in 2016 and matured in 2016. Lenders earned interest at 2% 5% - 37,000 Promissory notes issued in 2017 and matured in 2018. Lenders earn interest at 2% 5% 552,300 25,000 0.05 $ 25,000 577,300 Promissory note issued in 2018 and matured in 2019. Lender earned interest at 25% - 80,000 Promissory note issued in 2018 and matured in 2018. Lender earned interest at 2% 5% - 112,500 Promissory notes issued in 2018 and matured in 2019. Lenders earned interest at 2% 5% - 497,830 Promissory note issued in 2019 and matured in 2020. Lender earns 6% 231,481 231,478 Promissory note issued in 2019 and matured in 2019. Lender earned 6% - 10,000 Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15% 150,000 150,000 Promissory note issued in 2021 resulted from a Note Purchase Agreement with the original noteholder. The new notes reflected all principal, interest and penalties associated with the original instrument. The notes had an interest rate of 5% 7% 348,800 - 697,600 Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6% 0.05 65,000 - Promissory note issued in 2022 and matures in 2023. Lender earns interest at 6% 0.05 200,000 - $ 671,481 $ 3,070,208

Capital Structure _ Common St_2

Capital Structure – Common Stock and Stock Purchase Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Outstanding Common Stock Warrants	The following is a summary of outstanding common stock warrants as of September 30, 2022. Schedule of Outstanding Common Stock Warrants Expiration Date Number of Exercise Price Remaining Fourth Quarter 2022 9,811 $ 80 290 0.25 First Quarter 2023 4,000 $ 30 40 0.50 Second Quarter 2023 1,000 $ 200 0.75 Third Quarter 2023 501,500 $ 0.05 100 1.00 Third Quarter 2028 3,000 $ 70 6.00 Second Quarter 2032 28,995 $ 10 70 9.75 548,306 $ 0.05 290
Schedule of Stock Warrants Activity	Following is a summary of stock warrant activity for the nine months ended September 30 2022: Schedule of Stock Warrants Activity Number of Shares Exercise Weighted Average Price Warrants as of December 31, 2021 20,057,156 $ 2 290 $ 5.21 Issued - $ - $ - Expired and forfeited (2,283,850 ) $ 0.05 200 $ 126.76 Exercised (17,225,000 ) $ 0.05 $ 0.05 Warrants as of September 30, 2022 548,306 $ .05 70 $ 8.39
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Expected term (years) 0.63 Risk free rate 2.04 % Volatility 436 % Dividend yield -

Company Overview (Details Narra

Company Overview (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 185,447		$ 185,447
Stockholders' deficit	2,602,278	$ 7,743,645	2,602,278	$ 7,743,645	$ 7,948,256	$ 11,666,981
Net loss	2,493,455	(3,112,940)	3,257,151	(3,790,645)
Net income	$ (2,493,455)	$ 3,112,940	$ (3,257,151)	$ 3,790,645
Issuance of common stock upon warrant exercise, shares			81,615,483

Schedule of Basic and Diluted E

Schedule of Basic and Diluted Earnings per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Income available to common shareholders (Numerator)		$ 3,112,940		$ 3,790,645
Weighted average common shares	60,089,305	483,714	20,643,181	482,527
Basic EPS	$ (0.04)	$ 6.44	$ (0.16)	$ 7.86
Income available to common shareholders (Numerator)		$ 3,112,940
Weighted average common shares assuming exercise of outstanding warrants		12,507,218		12,507,218
Denominator	60,089,305	12,990,932	20,643,181	12,989,745
Diluted EPS	$ (0.04)	$ 0.24	$ (0.16)	$ 0.29

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended	9 Months Ended
	Sep. 20, 2022	Jun. 30, 2022	Sep. 30, 2022
Cash at federal deposit			$ 250,000
Issuance of shares for services, value			$ 95,973
Common Stock [Member]
Issuance of shares for services	50,000	49,500	99,500
Issuance of shares for services, value	$ 93,500	$ 2,463	$ 10
Share price	$ 1.87	$ 0.05

Investment in Common Stock of_2

Investment in Common Stock of Statera BioPharma, Inc. (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Impairment loss investment in common stock			$ 3,105,000	$ 2,645,000	$ 3,105,000
Cleveland BioLabs, Inc. [Member]
Stock issued, shares acquisitions						1,150,000
Statera BioPharma, Inc. [Member]
Impairment loss investment in common stock		$ 362,250

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes payable	$ 671,481	$ 3,070,208
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable		70,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable		606,500
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable		37,000
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable	25,000	577,300
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes payable		80,000
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Notes payable		112,500
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Notes payable		497,830
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Notes payable	231,481	231,478
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Notes payable		10,000
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Notes payable	150,000	150,000
Notes Payable Eleven [Member]
Short-Term Debt [Line Items]
Notes payable		697,600
Notes Payable Twelve [Member]
Short-Term Debt [Line Items]
Notes payable	65,000
Notes Payable Thirteen [Member]
Short-Term Debt [Line Items]
Notes payable	$ 200,000

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes payable	$ 671,481	$ 3,070,208
Notes Payable One [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	10%	10%
Penalty rate	5%	5%
Notes payable		$ 70,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	2%	2%
Penalty rate	5%	5%
Notes payable		$ 606,500
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	2%	2%
Penalty rate	5%	5%
Notes payable		$ 37,000
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	2%	2%
Penalty rate	5%	5%
Aggregate notes payable		$ 552,300
Convertible notes payble	$ 25,000	$ 25,000
Debt conversion, price	$ 0.05	$ 0.05
Notes payable	$ 25,000	$ 577,300
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	25%	25%
Notes payable		$ 80,000
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	2%	2%
Penalty rate	5%	5%
Notes payable		$ 112,500
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	2%	2%
Penalty rate	5%	5%
Notes payable		$ 497,830
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	6%	6%
Notes payable	$ 231,481	$ 231,478
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	6%	6%
Notes payable		$ 10,000
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	15%	15%
Notes payable	$ 150,000	$ 150,000
Notes Payable Eleven [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	5%	5%
Penalty rate	7%	7%
Notes payable		$ 697,600
Notes Payable Eleven [Member] | Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Notes payable	$ 348,800	$ 348,800
Notes Payable Twelve [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	6%	6%
Notes payable	$ 65,000
Notes Payable Twelve [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion, price	$ 0.05	$ 0.05
Notes Payable Thirteen [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	6%	6%
Notes payable	$ 200,000
Notes Payable Thirteen [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion, price	$ 0.05	$ 0.05

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Stock issued during period, shares	81,615,483
Promissory notes payable to shareholders	$ 375,000
Vendor and Employee [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument amount	$ 265,000
Debt instrument conversion price	$ 0.05
Note Holders [Member]
Short-Term Debt [Line Items]
Principal amount	$ 376,250
Warrant exercise price	$ 0.05
Note Holders One [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument amount	$ 1,209,206
Debt instrument conversion price	$ 0.05
Forte Animal Health, Inc. [Member]
Short-Term Debt [Line Items]
Stock issued during period, shares	2,235,000
Equity method investment, ownership percentage	15%
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member]
Short-Term Debt [Line Items]
Principal amount	$ 1,775,275
Promissory notes payable to shareholders		$ 1,775,275

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants (Details)	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	548,306
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.05
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 290
Fourth Quarter 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	9,811
Remaining Life (years)	3 months
Fourth Quarter 2022 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 80
Fourth Quarter 2022 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 290
First Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	4,000
Remaining Life (years)	6 months
First Quarter 2023 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 30
First Quarter 2023 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 40
Second Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	1,000
Exercise price	$ 200
Remaining Life (years)	9 months
Third Quarter 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	501,500
Remaining Life (years)	1 year
Third Quarter 2023 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 0.05
Third Quarter 2023 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 100
Third Quarter 2028 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	3,000
Exercise price	$ 70
Remaining Life (years)	6 years
Second Quarter 2032 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	28,995
Remaining Life (years)	9 years 9 months
Second Quarter 2032 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 10
Second Quarter 2032 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 70

Schedule of Stock Warrants Acti

Schedule of Stock Warrants Activity (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Warrants, Beginning balance | shares	20,057,156
Weighted Average Price, Beginning balance	$ 5.21
Number of Shares Warrants, Issued | shares
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares Warrants, Expired and forfeited | shares	(2,283,850)
Weighted Average Price, Expired and forfeited	$ 126.76
Number of Shares Warrants, Exercised | shares	(17,225,000)
Exercise Price, Exercised	$ 0.05
Weighted Average Price, Exercised	$ 0.05
Number of Shares Warrants, Ending balance | shares	548,306
Weighted Average Price, Ending balance	$ 8.39
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Beginning balance	2
Exercise Price, Expired and forfeited	0.05
Exercise Price, Ending balance	0.05
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Beginning balance	290
Exercise Price, Expired and forfeited	200
Exercise Price, Ending balance	$ 70

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Expected terms (in years)	7 months 17 days
Risk-free rate	2.04%
Expected volatility	436%
Expected dividends

Capital Structure _ Common St_3

Capital Structure – Common Stock and Stock Purchase Warrants (Details Narrative)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Warrants exercised	17,225,000
Charge resulting from warrant modification | $	$ 1,605,913
Warrant [Member]
Warrants exercised	17,225,000
Forfeited or cancelled | $ / shares	$ 2,283,850

Income Taxes _ Results of Ope_2

Income Taxes – Results of Operations (Details Narrative)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Statutory income tax rate	21%	21%

License Agreement with Forte _2

License Agreement with Forte Animal Health, Inc. (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Notes payable	$ 375,000
Stock issued during period, shares	81,615,483
Forte Animal Health, Inc. [Member]
Stock issued during period, shares	2,235,000
Equity method investment, ownership percentage	15%
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member]
Notes payable		$ 1,775,275
Interest payable		$ 264,790
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member] | Other Vendor and Employee [Member]
Interest payable	$ 1,125,086

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	Nov. 04, 2022	Nov. 13, 2022	Sep. 30, 2022	Oct. 23, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Outstanding principal on note			$ 671,481		$ 3,070,208
Common stock per share			$ 0.0001		$ 0.0001
Issuance of common stock upon exercise of warrant , shares			81,615,483
Unpaid interest			$ 134,678		$ 564,300
Cash payment			$ 500,000
Cash payment, description			In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
Description for monthly interest for payment			the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due.
Sublicense Occurs Before Completing a Clinical Trial [Member]
Subsequent Event [Line Items]
Royalty percentage			30%
Sublicense Occurs After Completing a Clinical Trial [Member]
Subsequent Event [Line Items]
Royalty percentage			10%
Sublicense Occurs After Any New Drug Application (NDA) [Member]
Subsequent Event [Line Items]
Royalty percentage			5%
Settlement Agreement And Release [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Outstanding principal on note				$ 25,000
Warrants of common shares conversion, shares				500,000
Warrants of common shares conversion per share				$ 0.05
Other accrued liabilities				$ 63,338
Common stock per share				$ 1
Issuance of common stock upon exercise of warrant , shares		563,338
Amendment Promissory Note And Settlement Litigation [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Outstanding principal on note	$ 150,000
Common stock per share	$ 0.50
Issuance of common stock upon exercise of warrant , shares	33,822
Payment on accrued interest	$ 60,000
Unpaid interest	$ 16,911
Conversion of stock shares issued	33,822
Accrued interest percentage	15%